I2Pure Iodine Breakthrough Sparks Deal Flow

Drs. Meehan & Johnston back I2Pure’s molecular iodine. ✅ Use this trigger to pitch non-antibiotic infection prevention. Next touch: book the demo and boost your pipeline.

Published on


Do not index
Do not index

🚀 Battle Card

🚀 Battle Card: I2Pure

Quick trigger:
 
👤 Decision Maker in the News
 
💡 Why It Matters
  • Top-tier clinical research on iodine formulations drives faster adoption of non-toxic infection prevention protocols. → Source
  • This I2Pure sales trigger underscores the urgency of scalable, antibiotic-alternative solutions in surgery.
 
🎯 Core Pain Point
  • Lack of validated surgical infection prevention tools in healthcare settings
  • Critical need to combat antibiotic resistance with non-antibiotic antimicrobials
 
💰 What to Pitch
  • Primary: Molecular iodine solutions → Reduce surgical site infections
  • Expansion: Research partnership and clinical validation support → Accelerate product adoption and evidence generation
 
🗺️ Quick Context
  • HQ: Ashburn, VA
  • Employees: ≈ 30
  • Rev: ≈ $5 M
 

🤼 Competitive Intel

*Which other vendors you’ll probably face to win I2Pure’s business in sales and marketing tech.*
 
  • Salesforce — CRM / Sales Cloud
    • Unique edge: End-to-end sales pipeline management
    • Evaluated by VP Sales & COO for enterprise scalability
  • HubSpot — CRM / Marketing Automation
    • Unique edge: Integrated inbound marketing tools
    • Evaluated by CMO & Dir. Marketing for content-driven lead gen
  • Marketo — Marketing Automation
    • Unique edge: Advanced campaign orchestration
    • Evaluated by Dir. Marketing for trade show and event engagement
  • Pardot — Marketing Automation
    • Unique edge: Native Salesforce integration
    • Evaluated by VP Sales for lead scoring alignment
  • Outreach — Sales Engagement
    • Unique edge: Automated multichannel sequences
    • Evaluated by Sales Ops for improving touch frequency
 

✅ Do-Now Checklist

Connect with Dr. Meehan & Dr. Johnston on LinkedIn (links above)
Drop first-touch email referencing the I2Pure sales trigger and schedule a demo
Log follow-ups in CRM for Days 3 & 10 and tag “I2Pure sales trigger”
 

Next Step

Get intel like this daily—no fluff, all pipeline. Subscribe to NewsletterForLeads
 

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑≈ TBD❑
OFFER_BRIEF   = ❑Non-toxic molecular iodine infection prevention solutions❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = ≈ TBD
COMPANY     = I2Pure
DEPT        = ≈ TBD
SIZE        = ≈ TBD
BOTTLENECK  = ≈ TBD
EVENT       = ≈ Celebrating achievements of Medical Advisors
DETAIL      = ≈ Celebrating achievements of Dr. John Meehan and Dr. Peter Johnston
PAIN        = Lack of validated surgical infection prevention tools in healthcare settings
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250916875066&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 30
REV_EST     = ≈ $5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ TBD-person ≈ TBD

≈ TBD—noticed your ≈ TBD team is ≈ TBD.

That’s when ≈ TBD slows growth.

We helped ≈ TBD fix this with Non-toxic molecular iodine infection prevention solutions.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Celebrating achievements of Dr. John Meehan and Dr. Peter Johnston — Lack of validated surgical infection prevention tools in healthcare settings.  
Non-toxic molecular iodine infection prevention solutions. ≈ TBD.  
Quick chat?

Join other 3200+ marketers now!

Ready to take the next big step for your business?

Subscribe